文献速递慢性肾脏病血液净化与透析

Evocalcet与西那卡塞治疗日本血透患者继发性甲旁亢的头对头比较

Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism.
PubMed 文献 · Kidney Int · 2018-07-24

Evocalcet在维持iPTH 60-240 pg/mL比例上非劣于西那卡塞(72.7% vs 76.7%,组间差-4.0% [95%CI -11.4%, 3.5%]),且胃肠道相关不良事件发生率显著更低(18.6% vs 32.8%)。

要点

  • Evocalcet在控制iPTH方面非劣于西那卡塞,达标率72.7% vs 76.7%。
  • Evocalcet胃肠道相关不良事件发生率显著低于西那卡塞(18.6% vs 32.8%)。
  • Evocalcet可作为血透患者继发性甲旁亢现有拟钙剂的有利替代选择。

核心结论

  • Evocalcet在抑制iPTH方面非劣于西那卡塞,且胃肠道相关不良事件更少,可能成为现有拟钙剂的有利替代。

研究设计与样本

  • 3期随机双盲双模拟头对头试验,日本血透合并继发性甲旁亢患者随机接受Evocalcet或西那卡塞(每组317例),治疗30周。

主要发现

  • Evocalcet组和西那卡塞组分别有72.7%和76.7%的患者达到目标iPTH水平(组间差-4.0% [95%CI -11.4%, 3.5%],非劣效性检验)。
  • 胃肠道相关不良事件发生率分别为18.6%和32.8%(组间差-14.2% [-20.9%, -7.5%],优效性检验显著)。

关键数值与推荐

  • 主要疗效终点为第28至30周平均iPTH达60-240 pg/mL的患者比例,非劣效界值-15%,采用符合方案集分析。

临床怎么用

  • 对于血透合并继发性甲旁亢患者,Evocalcet可替代西那卡塞用于控制iPTH,并可能减少胃肠道不良反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Secondary hyperparathyroidism (SHPT) leads to cardiovascular calcification, which affects survival and quality of life in patients with chronic kidney disease. Cinacalcet is used to control SHPT, but it may induce gastrointestinal symptoms, resulting in lower adherence and insufficient dosages. Therefore, a need exists to develop new calcimimetics that cause fewer gastrointestinal symptoms. Here we conducted a phase 3, randomized, double-blind, double-dummy trial for a head-to-head comparison of the efficacy and safety of evocalcet, a new oral calcimimetic, to the established cinacalcet. Japanese patients with SHPT on hemodialysis were randomized to receive evocalcet or cinacalcet (317 patients each) for 30 weeks. The primary efficacy endpoint was non-inferiority of evocalcet to cinacalcet in the proportion of patients achieving a mean intact parathyroid hormone level of 60 to 240 pg/mL from week 28 to 30 (non-inferiority margin, -15%, per protocol set analyses). In the evocalcet and cinacalcet groups, 72.7% and 76.7%, respectively, achieved the target intact parathyroid hormone level (between-group difference: -4.0% [95% confidence interval -11.4%, 3.5%], for non-inferiority). The incidence of gastrointestinal-related adverse events was 18.6% and 32.8%, respectively (between-group difference: -14.2% [-20.9%, -7.5%], significant for superiority). Thus, the non-inferiority of evocalcet to cinacalcet in suppressing intact parathyroid hormone with fewer gastrointestinal-related adverse events was demonstrated. Hence, evocalcet may be a favorable alternative to existing calcimimetics for management of SHPT.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Fukagawa M, Shimazaki R, Akizawa T, et al. Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int. 2018. PMID: 30049473. doi:10.1016/j.kint.2018.05.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。